Health Secretary Robert F. Kennedy Jr. has proposed that the Food and Drug Administration take a permissive approach toward unproven peptides, according to a report by Ars Technica — framing a stark regulatory question: whether products lacking demonstrated safety and effectiveness should face less restrictive federal oversight.
The report describes a sharply different view from FDA scientists, who said that none of the popular drugs being discussed had been demonstrated to be safe or effective. But what Kennedy specifically proposed for unproven peptides, how the FDA would carry it out and which products would fall within any new approach are not established in the available reporting. It is also unclear whether the proposal was formal policy, a recommendation or an idea raised for consideration.
How Unproven Peptides Reached the FDA Panel
The controversy over unproven peptides has been building all year. Kennedy, who has described himself as a “big fan” of peptides and said he has used them himself, directed the agency earlier this year to reconsider a short list of chemicals widely promoted by wellness influencers and fitness celebrities.
The FDA had previously placed BPC-157 and more than a dozen other injectable peptides on its list of substances considered too risky for pharmacies to compound, citing possible risks including contamination, allergic reactions and tumor growth.
In February, Kennedy told podcaster Joe Rogan he hoped to make several of the most hyped peptides — including Rogan’s beloved “Wolverine stack” — easier to obtain. Then on July 23, a Kennedy-reconstructed FDA advisory panel narrowly recommended adding six of seven unapproved peptide substances to the Section 503A bulks list.
That vote would eventually permit state-licensed pharmacies to compound the unproven peptides for individual patients with prescriptions — but only if the FDA formally accepts the recommendations through rulemaking. The vote did not make the peptides FDA-approved or immediately authorize their compounding.
The endorsed substances, promoted for conditions ranging from ulcerative colitis and wound healing to obesity, osteoporosis, insomnia and neurological disorders, include BPC-157, TB-500 and KPV. The only peptide not recommended was emideltide, pitched for opioid withdrawal, chronic insomnia and narcolepsy. Every affirmative vote was close: 8-6, 8-6, 8-6, 7-5, 7-4 and 8-5.
The vote tallies reflected the FDA advisory panel’s unusual makeup. Shortly before the meeting, eight new members — all appointed by the Kennedy-led Department of Health and Human Services — joined the committee. According to the New York Times, six had sold peptides or were affiliated with clinics, pharmacies or companies operating in the peptide market.
Enforcement Discretion and the White House Plan
The permissive posture toward unproven peptides may go further than the advisory vote. A new policy sent to the White House would essentially assure compounding pharmacies that they will not be targeted for producing certain peptides, according to two people familiar with the plan who spoke on condition of anonymity.
That approach, known as enforcement discretion, lets the FDA selectively decline to enforce some of its own regulations. The White House filing gives no specifics, but the people familiar with it say it is meant to allow compounding pharmacies to temporarily produce popular peptides including BPC-157, promoted to build muscle and heal injuries.
The update is the latest sign that Kennedy and other Trump administration officials are easing access to unproven peptides popular within the Make America Healthy Again movement, whose biggest figures sell peptide injections and supplements that remain widely available on platforms such as TikTok.
Unproven Peptides and the Safety Debate
Critics say loosening oversight of unproven peptides puts patients at risk. The FDA’s own staff scientists reiterated during the July review that none of the peptides had been studied enough to establish their safety and effectiveness — a conclusion that runs directly against the advisory panel’s recommendations.
Supporters of the Make America Healthy Again agenda counter that patients, physicians and pharmacists should decide. The standoff captures the central significance of the Ars Technica account: not simply a disagreement over how quickly a regulator should act, but over what should happen when the underlying evidence has not met the stated threshold.
What happens next is unclear. The FDA is not required to follow the advisory committee’s advice, though it usually does, and it is not known whether Kennedy’s reported proposal will become formal policy. For now, the permissive approach to unproven peptides remains a proposal described in reporting — one whose practical effect would depend entirely on boundaries that have not been made public.